Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-TriCAR-T/SILK in Non-Hodgkin Lymphoma
NCT03790891Phase 1Unknown
- Sponsor
- Timmune Biotech
- Start
- Jan 2019
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19-TriCAR-T in non-Hodgkin lymphoma (NHL), sponsored by Timmune Biotech. Primary endpoint: Incidence of treatment-related adverse events at 24 months. Status: unknown.
02
Drugs
CD19-TriCAR-T
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03790891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790891.